DS 1040

Drug Profile

DS 1040

Alternative Names: DS-1040b; DS1040

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Cardiovascular therapies
  • Mechanism of Action Carboxypeptidase U inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pulmonary embolism; Stroke

Most Recent Events

  • 14 Jun 2017 Daiichi Sankyo plans a phase I trial for Stroke in Japan (JapicCTI-173612)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Phase-I/II clinical trials in Pulmonary embolism (Adjunctive treatment, In the elderly, In adults) in Spain, Netherlands, Italy, Germany, France, France, Belgium and Austria (IV) after September 2016 (NCT02923115)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top